Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Proton Beam vs Intensity-Modulated Radiotherapy in Olfactory Neuroblastoma
Tang, Anthony , Krippaehne, Elise , Roozdar, Pooya, Goetschel, Kaitlin , Champagne, Pierre‐Olivier , Fernandez‐Miranda, Juan C. , Gardner, Paul , Hwang, Peter H. , Patel, Zara M. , Celda, María Peris, Sanusi, Olabisi , Snyderman, Carl H., Thorp, Brian D. , Zenonos, Georgios A. , Zwagerman, Nathan T. , Wang, Eric W., Olson, Brennan , Patel, Zara , Hwang, Peter H , Adida, Samuel , Donohue, Jack K. , Gago, Guilherme , Almeida, João Paulo , Nayak, Jayakar V. , Patel, Chirag, Pinheiro‐Neto, Carlos , Routman, David M. , Snyderman, Carl H , Gompel, Jamie J. Van , Wilke, Christopher , Wang, Eric W , Geltzeiler, Mathew , Choby, Garret

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | October 30, 2025 | Volume: 152 | Issue: 1 | Pages: 60

10.1001/jamaoto.2025.3816 | PMID 41165699 Get It

Importance Adjuvant radiotherapy can improve locoregional control and survival in patients with olfactory neuroblastoma (ONB), particularly with advanced-stage and histologic-grade disease. Standard radiotherapy treatment is with intensity-modulated radiotherapy (IMRT). Proton beam radiotherapy (PBRT) provides theoretical advantages in greater sparing of dose to uninvolved organs at risk. Objective To investigate if there are differences in the effectiveness and radiation treatment–related adverse events (RTAEs) between adjuvant IMRT and PBRT for patients with ONB. Design, Setting, and Participants This propensity score–matched cohort study included patients with ONB treated between February 2005 and April 2021 with either IMRT or PBRT at 9 academic tertiary care centers in North America. Patients were matched 1:2 based on age, modified Kadish stage, and Hyams grade. Data were analyzed from July 2024 to January 2025. Exposure Adjuvant IMRT or adjuvant PBRT. Main Outcomes and Measures Local recurrence-free survival (RFS), any RFS, and overall survival (OS). RTAEs, ie, grade 2 events or higher based on Common Terminology Criteria for Adverse Events, were recorded for both modalities. Results Of 54 included patients, 27 (50%) were female, and the mean (SD) age was 46.2 (15.4) years. A total of 18 were treated with PBRT and 36 were treated with IMRT. Most patients had modified Kadish stage C disease (33 of 54 [61%]), and 24 patients (44%) had Hyams grade III or IV disease. The RTAE rate was 20% (8 of 40); IMRT had a rate of 21% (6 of 29), and PBRT had a rate of 18% (2 of 11). The difference in the point estimates for 10-year RFS showed a potential clinical benefit favoring IMRT, although the wide confidence interval indicates uncertainty (10-year RFS: IMRT, 63.3%; 95% CI, 44.6-89.8; PBRT, 37.8%; 95% CI, 14.2-100; difference, 25.5 percentage points; 95% CI, −17.6 to 68.6). There were no clinically meaningful differences in 10-year local RFS (IMRT, 75.6%; 95% CI, 59.8-95.4; PBRT, 72.7%; 95% CI, 45.2-100; difference, 2.9 percentage points; 95% CI, −35.9 to 41.7) or 10-year OS (IMRT, 61.8%; 95% CI, 42.8-89.1; PBRT, 57.1%; 95% CI, 24.3-100; difference, 4.7 percentage points; 95% CI, −49.2 to 58.6), although wide confidence intervals indicate considerable uncertainty. Conclusions and Relevance Due to the imprecision of estimates, no definitive conclusions can be made regarding the comparative effectiveness of IMRT vs PBRT for patients with ONB. These preliminary data may inform the design of appropriately powered prospective studies evaluating the efficacy of PBRT vs IMRT in this population.
A Prognostic Signature for Lung Adenocarcinoma in Patients Who Have Never Smoked
Wei, Zhao , Zhang, Tongwu , Hua, Xing , Hoang, Phuc H. , Miraftab, Mona , Saha, Monjoy , McElderry, John, Sang, Jian , Lee, Olivia W. , Hartman, Caleb , Sharma, Sunandini , Colón-Matos, Frank J. , Anyaso‐Samuel, Samuel , Hutchinson, Amy , Hicks, Belynda , Rosenbaum, Jennifer, Zhong, Xiaoming , Yang, Yang , Leung, Kin Chung, Wong, Maria Pik , Mańczuk, Marta , Shangina, Oxana , Заридзе, Давид , Milosavljević, Saša , Ognjanovic, Simona , Savić, Milan , Gaborieau, Valérie , Brennan, Paul , Edell, Eric S. , Más, Luís , Chen, Chih‐Yi , Chang, I‐Shou , Hsiung, Chao A. , Liu, Geoffrey , Santamaría, Juan Miguel , Mutreja, Karun , Rothman, Nathaniel , Leduc, Charles , Sholl, Lynette M. , Lan, Qing , Yang, Lixing , Shi, Jianxin , Landi, Maria Teresa , Zhao, Wei , McElderry, John P , Khandekar, Azhar , Sharma, Sunandini , Colón-Matos, Frank J , Anyaso-Samuel, Samuel , Wang, Difei , Jones, Kristine , Hutchinson, Amy , Hicks, Belynda , Rosenbaum, Jennifer , Zhong, Xiaoming , Yang, Yang , Pesatori, Angela C , Consonni, Dario , Christiani, David C. , Leung, Kin Chung , Wong, Maria Pik , Manczuk, Marta , Lissowska, Jolanta , Świątkowska, Beata , Mukeria, Anush , Shangina, Oxana , Zaridze, David , Holcatova, Ivana , Mates, Dana , Milosavljevic, Sasa , Ognjanovic, Simona , Savic, Milan , Kontic, Milica , Gaborieau, Valerie , Brennan, Paul , Arrieta, Oscar , Bossé, Yohan , Schabath, Matthew B , Hofman, Paul , Mas, Luis , Yendamuri, Sai S , Chen, Chih-Yi , Chang, I-Shou , Hsiung, Chao Agnes , Liu, Geoffrey , Martinez Santamaría, Jacobo , Gould Rothberg, Bonnie E , Mutreja, Karun , Lawrence, Scott M. , Rothman, Nathaniel , Alexandrov, Ludmil B , Leduc, Charles , Baine, Marina K , Joubert, Philippe , Sholl, Lynette , Travis, William D , Homer, Robert , Lan, Qing , Chanock, Stephen Jacob , Yang, Lixing , Yang, Soo-Ryum , Shi, Jianxin , Landi, Maria T , Lissowska, Jolanta , Świątkowska, Beata , Holcátová, Ivana , Mateș, Dana , Arrieta, Óscar , Bossé, Yohan , Schabath, Matthew B. , Alexandrov, Ludmil B. , Travis, William D. , Homer, Robert

Mayo Clinic

Cancer Discovery | October 30, 2025 | Volume: 16 | Issue: 3 | Pages: 460-477

10.1158/2159-8290.cd-25-0581 | PMID 41165571 Get It

Abstract Understanding tumor cell dynamics can improve prognosis and treatment but remains limited for lung adenocarcinoma in people who have never smoked (NS-LUAD). With RNA sequencing data from 684 NS-LUAD cases and validation in an independent dataset, we identified three subtypes with distinct phenotypic traits and cell compositions. Additional genomic and histologic data further characterized the subtypes. “Steady,” marked by low proliferation, high alveolar cell fraction, moderate-to-well differentiation, and fewer driver gene alterations, is linked to prolonged survival and low immune evasion. “Proliferative” shows high proliferation markers, TP53 mutations, and gene fusions. “Chaotic,” with high epithelial-to-mesenchymal transition markers, has the worst prognosis, even within stage I tumors. Lacking known molecular or histologic characteristics, this aggressive subtype is solely identified by transcriptomic data. A 60-gene signature recapitulates the classification and predicts survival even within subgroups based on tumor stage or known genomic features, emphasizing its potential for improving early-stage NS-LUAD prognostication in clinical settings. Significance: The transcriptome of 684 NS-LUAD identifies three subtypes with different cellular dynamics and genomic and morphologic features. A 60-gene signature accurately stratifies subjects for mortality risk, even in stage I, offering a potential clinically applicable tool for treatment decision-making in patients with NS-LUAD. See related commentary by Azizi et al., p. 423
Generative diffusion model enables quantification of calibration‐free arterial spin labeling perfusion magnetic resonance imaging data in an Alzheimer's disease cohort
Shou, Qinyang , Ringman, John M. , Kim, Hosung , Jack, Clifford R. , Borowski, Bret, Arani, Arvin , Wang, Danny J.J. , Initiative, and for the Alzheimer's Disease Neuroimaging, Borowski, Bret J, Wang, Danny J J , Jack, Clifford R , Arani, Arvin , Cen, Steven , Chen, Nan‐kuei , Senjem, Matthew L. , Initiative, and for the Alzheimer's Disease Neuroimaging

Mayo Clinic

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | October 30, 2025 | Volume: 17 | Issue: 4 | Pages: No page available

10.1002/dad2.70214 | PMID 41181519 Get It

Abstract INTRODUCTION M0 images were missing in Siemens ASL data in Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset, prohibiting cerebral blood flow (CBF) quantification. METHODS A conditional latent diffusion model was trained and evaluated on in‐house datasets, then applied to the Siemens data in ADNI‐3. Regional CBF differences by Alzheimer's disease (AD) stages, their accuracy for AD classification, and CBF trajectory slopes were compared between generated data (Siemens) and acquired data (General Electric). RESULTS The diffusion model generated M0 images with high fidelity (SSIM = 0.918 ± 0.023, PSNR = 31.361 ± 2.537) and minimal CBF bias (mean difference is 0.21 ± 1.58 mL/100 g/min). Both generated and acquired CBF showed similar spatial patterns and decreasing trends with AD progression in specific AD‐related regions. Generated CBF also improved accuracy in classifying AD stages compared to qualitative perfusion images. CONCLUSION This study shows the potential of diffusion models for imputing missing modalities in large‐scale studies exploring the use of ASL as a biomarker of AD. Highlights Using latent diffusion model, we can generate M0 image from control image in arterial spin labeling (ASL) with high fidelity. The generated M0 can be used for cerebral blood flow (CBF) quantification in Alzheimer's Disease Neuroimaging Initiative dataset. The performance of classification between Alzheimer's disease (AD) patients and cognitive normal people is better when using generated CBF maps than using non‐quantitative perfusion images. ASL CBF decreases with AD progression in key AD‐related brain regions.
Investigating the Effects of Long-Term Fine Particulate Matter Exposure on Autism Spectrum Disorder Severity: Evidence from Multiple Analytical Approaches
Dou, Jianrui, Xie, Ruijin , Xu, Hua, Xiao, Xue, Luo, Yufan , Xu, Shiyu , Xiao, Wei, Wu, Dongqin , Zhang, Linpei , Sun, Chenyu , Liu, Yueying , Xie, Ruijin , Pan, Qiyang, Sun, Chenyu , Dou, Jianrui, Zhang, Kaiyue , Pan‐Hammarström, Qiang , Wang, Bin , Liu, Yueying

Mayo Clinic

Toxics | October 30, 2025 | Volume: 13 | Issue: 11 | Pages: 922

10.3390/toxics13110922 | PMID 41304474 Get It

With rapid industrial expansion, air pollution’s adverse neurological effects have gained increasing attention. Children face a greater risk of neurological damage because of their higher breathing rates, developing brains, and limited ability to detoxify harmful substances. Fine particulate matter has been identified as a primary neurotoxic contributor affecting developing brains. Strong evidence connects environmental pollutant exposure to the prevalence of Autism Spectrum Disorder (ASD), a neurodevelopmental condition marked by lasting difficulties with social communication and interaction. This study explores the association between long-term PM2.5 exposure and ASD symptom exacerbation, investigating underlying mechanisms. We hypothesize that long-term PM2.5 exposure exacerbates ASD symptoms through neuroinflammatory activation, leading to neuronal damage and impaired synaptic plasticity. Our investigation employs three complementary approaches: First, integrated analysis combining Global Burden of Disease data with Mendelian randomization demonstrates a significant association between PM2.5 exposure and increased ASD severity risk. Second, utilizing the China High-Resolution Air Pollution Database in conjunction with cohort studies, we provide evidence that ambient air pollution substantially influences autism severity, with PM2.5 identified as the predominant environmental determinant. Third, through network toxicology, single-cell transcriptomics, and animal experimentation, we demonstrate that chronic PM2.5 exposure exacerbates valproic acid-induced autism-like behaviors in murine models, identifying CTNNB1, PTEN, CCR2, AKT1, and mTOR as potential core mediating genes. Importantly, these findings represent preliminary results. Several potential confounding factors such as co-exposure to other pollutants and socioeconomic variables have not been fully addressed. While our multi-modal approach provides converging lines of evidence, further validation in larger, more diverse populations with refined control of confounders will be essential to establish causality and elucidate mechanisms. Nonetheless, these early insights advance our understanding of PM2.5-induced neurotoxicity in the context of ASD and offer timely, albeit preliminary, evidence to inform public health policy.
Sex-Specific Risks of Occupational Distress in Physicians Compared With the General Population
Shanafelt, Tait D. , Sinsky, Christine A. , Tutty, Michael , Carlasare, Lindsey E. , Trockel, Mickey , Shanafelt, Tait D , Dyrbye, Liselotte N. , Wang, Hanhan , West, Colin P.

Mayo Clinic

JAMA Network Open | October 29, 2025 | Volume: 8 | Issue: 10 | Pages: e2540060

10.1001/jamanetworkopen.2025.40060 | PMID 41160030 Get It

This survey study examines whether disparities in risk of burnout and low satisfaction with work-life integration by sex are similar among physicians compared with US workers in other fields.
Spatial multiomics of human hepatic lymph nodes reveals early APC bifurcation in liver transplant rejection
Nguyen, Justin H. , Ashraf, Humza, Moore, Raymond M. , Sherman, William H., Ma, Yaohua , Embretsen, Mattias , Cogen, Davitte , Kachergus, Jennifer M., Thompson, Cheryl L. , Killeen, Heather, Nakhleh, Raouf E. , Thompson, E. Aubrey , Knutson, Keith L. , Ashraf, Humza, Sherman, William, Thompson, Cheryl, Killeen, Heather E., Wang, Chen , Markovic, Svetomir N. , Knutson, Keith L.

Mayo Clinic

No container title available | October 28, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7901096/v1 Get It

Abstract The highest risk for liver allograft rejection is within the first weeks to months after a liver transplant; however, while later-stage mechanisms are well described, the initial window at the moment of alloantigen influx (e.g., ~ 1 h post-reperfusion) remains unmapped. T-cell priming is initiated in lymph nodes, yet these sites are rarely profiled in humans and their relationship to rejection risk is unclear. To address this gap, we profiled paired pre- and ~ 1 h post-reperfusion hepatic draining lymph nodes from liver transplant recipients using multiplexed immunofluorescence and GeoMx whole-transcriptome profiling to identify features that predict rejection versus non-rejection. Early after reperfusion, CD4 + and CD8 + T cells became proximal to macrophages in rejection compared to dendritic cells in non-rejection, which also displayed an immunoregulatory-leaning profile marked by PD-1, IDO1, and CD39, suggesting that macrophages and dendritic cells differentially influence early T-cell alloimmunity. These results provide nodal targets for precise immune modulation.
Using large language models to automate summarization of CT simulation orders in radiation oncology
Cao, Meiyun, Hu, S.X. , Sharp, Jason, Clouser, Edward , Lam, Louis, Ding, Xiaoning, Toesca, Diego Santos, Raulston, Brianne C, Lindholm, Wendy S., Patel, Samir H. , Vora, Sujay A., Wang, P. , Clouser, Edward Lee , Lam, Linda L, Wang, Peilong , Liu, Wei , Toesca, Diego A.S. , Hu, Shaw, Sharp, Jason, Holmes, Jason , Liu, Wei

Mayo Clinic

Journal of Applied Clinical Medical Physics | October 28, 2025 | Volume: 26 | Issue: 11 | Pages: No page available

10.1002/acm2.70310 | PMID 41144781 Get It

Abstract Background In the current clinical workflow of radiation oncology, therapists manually summarize the physician‐issued Computed Tomography (CT) simulation orders to prepare patients' CT simulations. This process increases the workload, introduces variability in documentation quality, and is prone to human errors. Purpose This study aims to address these challenges using a large language model (LLM) to automate the generation of summaries from the CT simulation orders and evaluate its performance. Methods A total of 607 CT simulation orders were collected from the Aria database at our institution. A locally hosted LLaMa 3.1 405B model, accessed via the Application Programming Interface (API) service, was used to extract keywords from the CT simulation orders and generate summaries. The downloaded CT simulation orders were categorized into seven groups based on treatment modalities and disease sites. For each group, a customized instruction prompt was developed collaboratively with therapists to guide the LLaMa 3.1 405B model in generating summaries. The ground truth for the corresponding summaries was manually derived by carefully reviewing each CT simulation order and subsequently verified by therapists. The accuracy of the LLM‐generated summaries was evaluated by therapists using the ground truth. Results Over 98% of the LLM‐generated summaries aligned with the ground truth in terms of accuracy. Our evaluations showed an improved consistency in format and enhanced readability from the LLM‐generated summaries compared to the corresponding therapist‐generated summaries. This automated approach demonstrated consistent performance across all groups, regardless of treatment modality or disease site. Conclusions This study demonstrated the high precision and consistency of the LLaMa 3.1 405B model in extracting keywords and summarizing CT simulation orders, suggesting that LLMs have great potential to assist in this task, reduce the workload of CT simulation therapists and improve radiation oncology workflow efficiency.
The effects of dry needling and therapeutic exercise on sleep in individuals with chronic neck pain and sleep disturbance: a feasibility randomized clinical trial
Lunasin, Ray M. , Cleland, Joshua A. , Brizzolara, Kelli , Weber, Mark L. , Wang‐Price, Sharon , Lunasin, Ray , Cleland, Joshua , Weber, Mark

Mayo Clinic

Journal of Manual & Manipulative Therapy | October 28, 2025 | Volume: 34 | Issue: 3 | Pages: 217-229

10.1080/10669817.2025.2581047 | PMID 41147514 Get It

Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell Lymphoma
Cliff, Edward R. Scheffer , Pelaez, Guido D. , Wan, Fei , Iyengar, Varun , Zhou, Jihao , Chung, Kevin , Abdel-Razeq, Nayef , Allen, J. , Major, Ajay , Sharp, John , Gould, Patrick , Houshyar, Samin , Lynch, Ryan C. , Fleyshman, Michelle , Kidwell, Adam , Fenske, Timothy S. , Malakhov, Nikita , Mulvey, Erin , Nowakowski, Grzegorz S. , Torka, Pallawi , Russler‐Germain, David A. , Allen, Jessica , Epperla, Narendranath , Gould, Patrick , Cherng, Hua-Jay J , Houshyar, Samin , Wallace, Danielle S , Lynch, Ryan C , Kallam, Avyakta , Mei, Matthew , Merryman, Reid W , Fleyshman, Michelle , Rhodes, Joanna , Kidwell, Adam , Fenske, Timothy S , Malakhov, Nikita , Mulvey, Erin , Watkins, Marcus , Moustafa, Muhamad Alhaj , Hilal, Talal , Nowakowski, Grzegorz S , Wang, Yucai , Torka, Pallawi , Russler-Germain, David A , Major, Ajay , Sharp, John , Zhou, Jihao , Epperla, Narendranath , Cherng, Hua‐Jay J. , Wallace, Danielle , Kallam, Avyakta , Mei, Matthew , Merryman, Reid W. , Rhodes, Joanna , Watkins, Marcus P. , Moustafa, Muhamad Alhaj , Hilal, Talal , Wang, Yucai

Mayo Clinic

Clinical Cancer Research | October 27, 2025 | Volume: 32 | Issue: 1 | Pages: 159-168

10.1158/1078-0432.ccr-25-2392 | PMID 41143601 Get It

Abstract Purpose: Polatuzumab vedotin (polatuzumab) was approved for up-front treatment of diffuse large B-cell lymphoma in combination with chemoimmunotherapy (Pola-R-CHP) based on the POLARIX trial. However, when stratified by cell of origin (COO), polatuzumab seems to have greater efficacy in activated B-cell than germinal center B-cell (GCB) subtype disease. Most studies of polatuzumab used RNA expression to assess COO, whereas in routine clinical practice, the immunohistochemistry-based Hans algorithm is used. Experimental Design: To assess the impact of COO by immunohistochemistry on polatuzumab efficacy, we conducted a multicenter real-world study of adults with large B-cell lymphoma (LBCL) receiving polatuzumab from 2015 to 2024, split by receipt of polatuzumab in first-line versus relapsed/refractory settings. The primary endpoint was overall response rate (ORR) to polatuzumab-based treatment in GCB versus non-GCB relapsed/refractory LBCL. Results: Of 740 patients, 305 received polatuzumab in the first-line setting and 435 in the relapsed/refractory setting. In the relapsed/refractory cohort, the ORR in non-GCB versus GCB LBCL was 59.7% versus 36.3% [OR, 2.6; 95% confidence interval (CI), 1.77–3.84; P < 0.0001], with a complete response rate of 35.7% versus 17.7% (OR, 2.6; 95% CI, 1.66–4.02; P < 0.0001). Progression-free survival was longer for patients with non-GCB versus GCB COO (HR, 0.64; 95% CI, 0.5–0.83; P = 0.0006). In the first-line cohort, ORR, complete response rate, and progression-free survival were similar in non-GCB versus GCB LBCL, as hypothesized based on outcomes in the Pola-R-CHP arm of POLARIX, suggesting that the addition of polatuzumab overcomes the adverse risk of non-GCB COO in patients receiving R-CHOP. Conclusions: Based on these data, COO classification by the Hans algorithm is a strong predictor of polatuzumab efficacy in LBCL, informing real-world treatment decisions.
CDK12-Mediated Phosphorylation of FOXA1 Promotes Prostate Cancer Progression via the MDM2–p53 Axis
Yan, Binyuan, Huang, Mengjun, Wang, Jinxiang , Lei, Hanqi, Tong, Tongyu , Xu, Bin , Cao, Fei, Teng, Qiliang, Mao, Wenjun, Yan, Binyuan , Pang, Jun , Yan, Binyuan , Yan, Binyuan, Huang, Mengjun, Lei, Hanqi, Teng, Qiliang, Huang, Jinsheng , Guan, Yupeng , Mao, Wenjun, Huang, Haojie , Pang, Jun

Mayo Clinic

Research | October 27, 2025 | Volume: 8 | Issue: No issue available | Pages: No page available

10.34133/research.0990 | PMID 41395253 Get It

Prostate cancer (PCa) progression is driven by intricate molecular mechanisms involving dysregulated signaling networks and posttranslational modifications of key regulatory proteins. In this study, we identify a novel oncogenic pathway wherein cyclin-dependent kinase 12 (CDK12) physically interacts with and phosphorylates forkhead box A1 (FOXA1) at serine 234 (S234). Phosphorylation at this residue markedly enhances FOXA1 transcriptional activity, leading to up-regulation of downstream targets including murine double minute 2 (MDM2), a critical negative regulator of the p53 tumor suppressor. Mechanistically, this CDK12–FOXA1–MDM2 axis destabilizes p53, attenuates apoptotic signaling, and promotes PCa cell survival and proliferation. Therapeutic targeting of CDK12 using the small-molecule inhibitor THZ531 or RNA interference effectively abrogates FOXA1 phosphorylation, restores p53 stability, reactivates apoptotic pathways, and suppresses tumor growth. Notably, the identification of S234 as a functional phosphorylation site in FOXA1 reveals a previously uncharacterized posttranslational regulatory mechanism in PCa biology. These findings establish the CDK12–FOXA1–MDM2 axis as a pivotal driver of PCa progression and underscore the therapeutic potential of targeting FOXA1 phosphorylation to restore tumor suppressor function and induce apoptosis in PCa. Our work provides a mechanistic framework for developing precision therapies aimed at disrupting this oncogenic cascade in PCa.